**Supplementary Table 2**

**Association between GLUT-1 expression and recurrence-free survival in patients with pancreatic cancer who underwent upfront surgery (n = 100)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | |  | **Univariate analysis** | | **Multivariate analysis** | |
| **Factor (n)** | | **Events** | **MST (months)** | **P-value** | **Adjusted HR**  **(95% CI)** | **P-value** |
| Age (years) | < 75 (70)  ≥ 75 (30) | 59  19 | 10.0  16.5 | 0.089 |  |  |
| Gender | Male (60)  Female (40) | 50  28 | 8.0  19.0 | 0.004 | 1.865  (1.141–3.048) | 0.013 |
| Tumor position | Head (69)  Body-tail (31) | 55  23 | 12.0  10.0 | 0.653 |  |  |
| Tumor size | ≤ 30 mm (58)  > 30 mm (42) | 43  35 | 16.0  6.0 | 0.003 | 1.404  (0.828–2.381) | 0.207 |
| T factor | 1/2 (6)  3 (94) | 5  73 | 14.5  12.0 | 0.589 |  |  |
| N factor | 0 (35)  1 (65) | 22  56 | 28.0  9.0 | <0.001 | 0.357  (0.198–0.645) | <0.001 |
| Histology | WD (48)  MD/PD (52) | 32  46 | 19.0  10.0 | 0.004 | 2.244  (1.345–3.742) | 0.002 |
| CA 19-9 | ≤ 37 U/mL (41)  > 37 U/mL (59) | 27  51 | 28.0  6.0 | <0.001 | 0.357  (0.211–0.604) | <0.001 |
| R0 resection | No (23)  Yes (77) | 21  57 | 9.0  14.3 | 0.010 | 2.760  (1.580–4.823) | <0.001 |
| GLUT-1 expression | Low (40)  High (60) | 29  49 | 17.0  9.4 | 0.010 | 0.458  (0.269–0.778) | 0.004 |
| Postoperative adjuvant therapy | No (35)  Yes (65) | 27  51 | 9.0  16.0 | 0.149 |  |  |
| *CA 19-9*, carbohydrate antigen 19-9; *CI*, confidence interval; *GLUT-1*, glucose transporter type 1; *HR*, hazard ratio; *MD*, moderately differentiated; *MST*, median survival time; *PD*, poorly differentiated; *WD*, well-differentiated | | | | | | |